Genentech Inc. (Roche) reports that the primary endpoint has been met for the Phase III HAVEN 1 study evaluating emicizumab (ACE910) prophylaxis in people 12 years of age or older with hemophilia A and inhibitors to Factor VIII.
Emicizumab, discovered by Chugai Pharmaceutical Co. Ltd., is a bispecific monoclonal antibody designed to bring together Factors IXa and...





